Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 06 January 2017 | By Michael Mezher
The US Food and Drug Administration's (FDA) Center for Biologics Research and Evaluation (CBER) has once again met or exceeded its performance goals for reviewing and acting on product applications and supplements, according to a report released Thursday from CBER Director Peter Marks.
The report is Marks' first since he rose to head CBER last January, replacing former CBER Director Karen Midthun after her 22-year stint at the agency.
As in previous years, CBER met or exceeded the performance goals for product reviews established by the various User Fee Acts:
Compared with 2015, CBER saw fewer Biologic License Applications (BLAs) with eight BLAs falling within the FY2016 review timeframe as opposed to 13 in FY2015.
Aside from hitting its performance targets for reviews, CBER published a total of 12 guidance documents in FY2016, four of which were published in cooperation with the Center for Drug Evaluation and Research (CDER) or the Center for Devices and Radiological Health (CDRH).
The guidances include four final guidances and six draft guidances, as well as two guidances for immediate implementation intended to reduce the risk of Zika virus transmission.
FY2016 Report from the Director
Tags: CBER, PDUFA, MDUFA, BLA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.